C4 Therapeutics (CCCC) News Today $3.91 -0.15 (-3.69%) (As of 12/4/2024 05:53 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $10.00December 2 at 4:07 AM | americanbankingnews.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Bought by Wasatch Advisors LPWasatch Advisors LP grew its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 17.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,677,368 shares of the company's stock after purchasing an additional 830,218 shares durDecember 1, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Hold" from AnalystsC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has been given an average recommendation of "Hold" by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommeNovember 25, 2024 | marketbeat.comC4 Therapeutics appoints Hoerter to board of directorsNovember 22, 2024 | markets.businessinsider.comC4 Therapeutics Appoints Steve Hoerter to BoardNovember 21, 2024 | markets.businessinsider.comC4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of DirectorsNovember 20, 2024 | globenewswire.comStephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight RecommendationNovember 19, 2024 | msn.comC4 Therapeutics initiated with an Equal Weight at StephensNovember 18, 2024 | markets.businessinsider.comC4 Therapeutics (NASDAQ:CCCC) Now Covered by Analysts at StephensStephens assumed coverage on shares of C4 Therapeutics in a research note on Monday. They set an "equal weight" rating and a $4.00 price objective for the company.November 18, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short InterestC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 5,850,000 shares, a decrease of 12.0% from the October 15th total of 6,650,000 shares. Based on an average trading volume of 975,000 shares, the days-to-cover ratio is currently 6.0 days.November 16, 2024 | marketbeat.comC4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical TrialNovember 7, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for C4 Therapeutics (CCCC)November 7, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Hold Rating on C4 Therapeutics (CCCC)November 5, 2024 | markets.businessinsider.comC4 Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 2, 2024 | finance.yahoo.comC4 Therapeutics Advances in Protein Degradation TherapyNovember 1, 2024 | markets.businessinsider.comC4 Therapeutics files $400M mixed securities shelfOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics files to sell 4.87M shares of common stock for holdersOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by BrokeragesC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buOctober 31, 2024 | marketbeat.comWe're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash WiselyOctober 29, 2024 | finance.yahoo.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 28, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest UpdateC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 6,650,000 shares, a decline of 39.6% from the September 30th total of 11,010,000 shares. Based on an average trading volume of 988,500 shares, the days-to-cover ratio is currently 6.7 days.October 26, 2024 | marketbeat.comC4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.October 17, 2024 | finanznachrichten.deC4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.October 15, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC lowered its position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 26.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 560,959 shares of the company's stockOctober 12, 2024 | marketbeat.comC4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity SummitOctober 9, 2024 | globenewswire.comRenaissance Technologies LLC Sells 170,600 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Renaissance Technologies LLC cut its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 42.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 235,200 shares of the company's stock afterOctober 7, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Hold" from BrokeragesShares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given a consensus recommendation of "Hold" by the seven brokerages that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and three have issued a buy rating on the comOctober 6, 2024 | marketbeat.comPoint72 Asset Management L.P. Sells 627,892 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Point72 Asset Management L.P. reduced its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 69.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 278,580 shares of the company's stock after seOctober 4, 2024 | marketbeat.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 30, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) is Lynx1 Capital Management LP's 4th Largest PositionLynx1 Capital Management LP lifted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 89.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,880,527 shares of the company's stock after buying anSeptember 27, 2024 | marketbeat.comBank of New York Mellon Corp Takes Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)Bank of New York Mellon Corp acquired a new position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 190,761 shares of the company's stock, valued at approximately $881,000. Bank of NeSeptember 22, 2024 | marketbeat.comCCCC Oct 2024 12.000 callSeptember 21, 2024 | ca.finance.yahoo.comAcadian Asset Management LLC Buys 91,443 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Acadian Asset Management LLC increased its stake in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 415.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 113,436 shares of the company's stock after acquiSeptember 19, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short InterestC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 11,630,000 shares, an increase of 10.8% from the August 15th total of 10,500,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is currently 7.4 days.September 17, 2024 | marketbeat.comCautious Hold Rating on C4 Therapeutics Amid Modest Efficacy and Pending DataSeptember 16, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)September 16, 2024 | markets.businessinsider.comHold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market CautionSeptember 15, 2024 | markets.businessinsider.comC4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024September 13, 2024 | globenewswire.comBMO maintains Outperform rating on C4 Therapeutics stockSeptember 11, 2024 | uk.investing.comAnalyst maintains Buy on C4 Therapeutics shares, notes early signs of BRAF degrader efficacySeptember 11, 2024 | uk.investing.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by BrokeragesC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average recommendation of "Hold" from the seven analysts that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to tSeptember 11, 2024 | marketbeat.comC4 Therapeutics, Inc.: C4 Therapeutics Announces Delivery of Second Development Candidate to BiogenSeptember 10, 2024 | finanznachrichten.deC4 Therapeutics Announces Delivery of Second Development Candidate to BiogenSeptember 10, 2024 | markets.businessinsider.comC4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024September 8, 2024 | globenewswire.comC4 Therapeutics (CCCC) Gets a Buy from Stifel NicolausSeptember 5, 2024 | markets.businessinsider.comC4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of DirectorsSeptember 3, 2024 | globenewswire.comC4 Therapeutics to Participate in Upcoming September Investor ConferencesAugust 29, 2024 | globenewswire.comC4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC)C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors purchased 10,243 put options on the company. This is an increase of approximately 2,146% compared to the average volume of 456 put options.August 27, 2024 | marketbeat.comHennion & Walsh Asset Management Inc. Makes New Investment in C4 Therapeutics, Inc. (NASDAQ:CCCC)Hennion & Walsh Asset Management Inc. bought a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 142,832 shares of the company's stoAugust 21, 2024 | marketbeat.com Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address 3 Under-$10 Stocks That Could Skyrocket (Ad)Looking for affordable stocks that could deliver big returns? Our latest report showcases 3 buy-rated stocks under $10 that analysts believe have major upside potential. Don’t miss out on these hidden opportunities that could boost your portfolio. Download Your Free Report Today. CCCC Media Mentions By Week CCCC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CCCC News Sentiment▼0.660.79▲Average Medical News Sentiment CCCC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CCCC Articles This Week▼23▲CCCC Articles Average Week Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANI Pharmaceuticals News Today Calliditas Therapeutics AB (publ) News Today Septerna News Today Gyre Therapeutics News Today Avadel Pharmaceuticals News Today Bicara Therapeutics News Today Cogent Biosciences News Today 89bio News Today Nuvation Bio News Today Collegium Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CCCC) was last updated on 12/5/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
